Zydus LifeSciences Q4 Results Review - Niche Products, Superior Execution Boost Earnings: Motilal Oswal

Motilal Oswal Report

Zydus Lifesciences Ltd. delivered a better-than-expected Q4 FY24 performance, driven by increased off-take in the U.S./Europe/active pharma ingredient segments. Zydus Lifesciences saw better growth than the industry in the domestic formulation market.

It ended FY24 on a strong note with 13%/41%/65% YoY growth in revenue/Ebitda/profit after tax.

We raise our earnings estimates by 12%/14% for FY25/FY26 to factor in-

1. niche launches/increased traction in commercialised limited competition products,

2. increasing share of chronic therapies in the DF segment, and

3. a gradual recovery in demand for consumer healthcare products.

We value Zydus Lifesciences at 24 times 12 months forward earnings to arrive at a target price of Rs 1,045.

Zudus Lifesciences is in good stead to maintain growth momentum in its key markets of US/DF.

It continues to work on complex products, including peptides, transdermals and injectables for regulated markets, as well as innovation products for global markets.

While the outlook is promising, the valuation factors in the earnings upside adequately. Maintain Neutral on the stock.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.